scholarly journals Efficacy and Side Effect of Docetaxel Based Chemotherapy as Second-Line Treatment in Recurrent Gastric Cancer

2007 ◽  
Vol 24 (2 Suppl) ◽  
pp. S399-406
Author(s):  
Se Won Kim ◽  
Sang Woon Kim ◽  
Sun Kyo Song
Keyword(s):  
Gastric Cancer ◽  
Side Effect ◽  
Line Treatment ◽  
Second Line ◽  
Recurrent Gastric Cancer

Feasibility of sequential fixed S-1 followed by paclitaxel for the treatment of advanced or recurrent gastric cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 15113-15113
Author(s):  
M. Ohashi ◽  
T. Kanda ◽  
K. Yajima ◽  
H. Honma ◽  
S. Kosugi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Treatment Time ◽  
Performance Status ◽  
Single Agent ◽  
Line Treatment ◽  
Second Line ◽  
First Line ◽  
Second Line Chemotherapy ◽  
Recurrent Gastric Cancer ◽  
Line Chemotherapy

15113 Background: First-line chemotherapy for advanced/recurrent gastric cancer has limited efficacy, achieving a median survival time (MST) of about 7 months, while addition of second-line and subsequent chemotherapy may prolong MST to about 11.5 months. In practice, however, about half of patients failing with first-line chemotherapy are unable to receive second-line chemotherapy because of worsening of their performance status (PS), disease progression, or toxicities during protracted first-line chemotherapy. We studied the feasibility of a sequential fixed regimen devised to ensure prompt initiation of second-line chemotherapy after first-line failure. Methods: Between December 2002 and December 2006, patients with advanced or recurrent gastric cancer were enrolled who met the following requirements: 1) major organ function preserved; 2) PS 0–2; 3) presence of at least one evaluable lesion; and 4) written informed consent. The treatment regimen consisted of 3 courses of single-agent S-1 or S-1/cisplatin combination followed by weekly paclitaxel (wPTX). The endpoints of the study were entry to the second-line treatment, time to failure (TTF), and MST. Results: Of 39 patients enrolled, 37 completed first- line S-1. Twenty-eight patients (76%) then received wPTX, 2 non-wPTX chemotherapy, and 6 surgery; only 1 received no additional treatments. Second-line wPTX was followed by a third-line treatment in 23/28 patients (82%). The TTF with the sequential fixed regimen was 7 months. The MST and the 1- and 2-year survival rates in the 37 completing first-line treatment were 14.6 months, 61% and 25%, while those in the 28 switched over to wPTX were 12.5 months, 51% and 17%. Conclusions: Patients with advanced/recurrent gastric cancer treated sequentially with a fixed number of courses of S-1 followed by wPTX may have a good chance of treatment continuation. A sequential fixed regimen may further improve survival of patients with advanced/recurrent gastric cancer only with combinations of currently available drugs. No significant financial relationships to disclose.

scholarly journals Phase I/II Study of Weekly Oraxol for the Second‐Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer

2015 ◽  
Vol 20 (8) ◽  
pp. 896-897 ◽  
Author(s):  
Keun‐Wook Lee ◽  
Kyung Hee Lee ◽  
Dae Young Zang ◽  
Young Iee Park ◽  
Dong Bok Shin ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase I ◽  
Line Treatment ◽  
Second Line ◽  
Recurrent Gastric Cancer

Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle as second-line treatment for advanced or recurrent gastric cancer.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 4041-4041 ◽  
Author(s):  
K. Chin ◽  
K. Kato ◽  
T. Yoshikawa ◽  
K. Yamaguchi ◽  
T. Esaki ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Line Treatment ◽  
Second Line ◽  
Recurrent Gastric Cancer

scholarly journals P44-4 A case report of four patients received ramucirumab monotherapy as second-line treatment for advanced gastric cancer

2021 ◽  
Vol 32 ◽  
pp. S353
Author(s):  
Kei Onodera ◽  
Akiko Ichiyanagi ◽  
Akari Ueno ◽  
Motohiro Tani ◽  
Shuji Sato ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Case Report ◽  
Advanced Gastric Cancer ◽  
Line Treatment ◽  
Second Line

Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1

2007 ◽  
Vol 12 (2) ◽  
pp. 146-149 ◽  
Author(s):  
Wataru Arai ◽  
Yoshinori Hosoya ◽  
Masanobu Hyodo ◽  
Hidenori Haruta ◽  
Kentaro Kurashina ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Weekly Paclitaxel ◽  
Line Treatment ◽  
Second Line

scholarly journals Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer

2006 ◽  
Vol 9 (1) ◽  
pp. 14-18 ◽  
Author(s):  
Shuichi Hironaka ◽  
Sadamoto Zenda ◽  
Narikazu Boku ◽  
Akira Fukutomi ◽  
Takayuki Yoshino ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Weekly Paclitaxel ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Recurrent Gastric Cancer ◽  
Line Chemotherapy

Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study

2019 ◽  
Vol 10 (4) ◽  
pp. 591-597 ◽  
Author(s):  
Valentina Fanotto ◽  
Lorenzo Fornaro ◽  
Roberto Bordonaro ◽  
Gerardo Rosati ◽  
Lorenza Rimassa ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Real World ◽  
Treatment Efficacy ◽  
Older Patients ◽  
Line Treatment ◽  
Second Line
Sign in / Sign up

Export Citation Format

Share Document